ALB and stroke disorder: The ROCKET (Rivaroxaban Once‐daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial) trial also identified reduced serum albumin and platelet count,6 two parameters that were not available for patients in this study.